Vendor Intelligence Report: NuLife Peptides

Executive summary

NuLife Peptides is a new, account-gated vendor with a better early lab signal than its paper trail would suggest. Across 12 Finnrick lab tests the overall result is 11 pass / 1 fail, a 92% pass rate. The signal is selective rather than uniform: Retatrutide is the clearest positive NuLife case, while PT-141 is the product that needs the most caution; BPC-157 sits in the middle, and CJC-1295/TB-500 look weaker when ratings, not just pass counts, are considered.

The OSINT record changes the picture. Public records place the current web operation and Nevada LLC in a tight late-2025 launch window, while the branded health-holdings story appears later and is not matched by the registry trail. NuLife markets a vertically integrated platform, US manufacture, COAs, telehealth, and 503B-adjacent fulfillment language; the full investigation verifies only a much narrower legal footprint and finds the telehealth arm non-operational as observed.

Ownership transparency is also incomplete. NuLife’s pages do not name officers, operators, physicians, chemists, or facility personnel; attribution depends on prior brand-use evidence and a co-hosted personal-domain cluster on a shared GoDaddy server. No FDA warning letter, court action, Trustpilot page, or BBB listing surfaced, but the short operating history, login wall, zero archive history, and unavailable public COA samples keep this from being a clean reputation case.

For buyers, the practical read is product-specific. NuLife’s current lab record supports selective consideration, especially where the Finnrick data is strongest, but it does not validate the holding-company narrative, domestic manufacturing claim, or broad catalog quality.

Inside the full report:

• Appendix A with per-product pass/fail rates, Finnrick ratings, and methodology-divergence charts for all 6 tested products
• Launch timeline tying domain registration, SSL issuance, Nevada LLC filing, terms effective date, and later NuLife Bio Health registration
• Corporate registry comparison of claimed holding-company structure versus verified Nevada SOS and OpenCorporates results
• Reverse-IP/domain-cluster analysis covering NuLife retail, wholesale, telehealth, Bio Health, and co-hosted personal-name domains
• Operator attribution analysis using prior NuLife brand references, co-hosted domains, and public professional profiles
• Regulatory, telehealth, COA/manufacturing, reputation, affiliate-promotion, and dead-end checks

Risk assessment

• Misleading corporate-scale claims — high: NuLife Bio Health presents a holding-company/subsidiary structure, but searches found only NuLife Peptides LLC and no registered NuLife Bio Health, Wholesale, TeleMed, Longevity, or Health Nut entities.
• Unverifiable US manufacturing and COA transparency — medium: The site claims USA manufacturing and COAs, but no facility address, FDA registration, named manufacturer, or public sample COAs were disclosed.
• Non-operational telehealth and 503B claims — medium: NuLife TeleMed is marketed with physician-reviewed and 503B-delivery language, but nulifetelemed.com returned a blank page and no partners or licensing were verified.
• Ownership and management opacity — medium: Public NuLife pages name no owners or officers; OSINT points to Greg Rankich and possibly Savannah Rankich, but Nevada records do not confirm members or managers.
• PT-141 quality consistency concern — medium: PT-141 is the only Finnrick-tested product with a failure, at 1 pass / 1 fail across 2 tests; Retatrutide is the stronger NuLife choice at 80.97%.
• Retatrutide regulatory concern — medium: Retatrutide is investigational and identified in the supplied legal source as outside routine 503A compounding; concern is specific to Retatrutide buyers.
• Short operating history and thin public reputation — medium: Domain registration, SSL issuance, and LLC formation cluster in late 2025, with zero Wayback captures and no Trustpilot or BBB footprint found.
• Catalog-gating due-diligence barrier — medium: The mandatory login wall blocks public catalog and COA inspection before account creation, reducing buyer visibility and complicating external monitoring.